Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/28835
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSymonds, ALJ-
dc.contributor.authorMiao, T-
dc.contributor.authorBusharat, Z-
dc.contributor.authorLi, S-
dc.contributor.authorWang, P-
dc.date.accessioned2024-04-22T08:21:43Z-
dc.date.available2024-04-22T08:21:43Z-
dc.date.issued2022-11-07-
dc.identifierORCiD: Alistair L. J. Symonds https://orcid.org/0000-0002-9461-0816-
dc.identifierORCiD: Suling Li https://orcid.org/0000-0001-8756-9336-
dc.identifierORCiD: Ping Wang https://orcid.org/0000-0001-8992-1233-
dc.identifier.citationSymonds, A.L.J. et al. (2023) 'Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells', Cancer Immunology, Immunotherapy, 72 (5), pp. 1139 - 1151. doi: 10.1007/s00262-022-03319-w.en_US
dc.identifier.issn0340-7004-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/28835-
dc.descriptionData availability: The RNA-seq data generated in this study are available from the ArrayExpress website (www.ebi.ac.uk/arrayexpress) under accession number: E-MTAB-11672.en_US
dc.descriptionSupplementary Information is available online at: https://link.springer.com/article/10.1007/s00262-022-03319-w#Sec19 .-
dc.description.abstractAlthough T cells can develop into an exhausted state in the tumour microenvironment, tumour infiltrating T cells (TILs) are important to control tumour growth. By analysing single cell RNA-sequencing data from human tumours, we found that the transcription factors Early Growth Response 2 (EGR2) and 3 were highly induced in TILs, but not peripheral CD8 + T cells, in multiple patient cohorts. We found that deficiency of Egr2 and 3 in T cells resulted in enhanced tumour growth and fewer TILs in mouse models. Egr2 is highly expressed together with checkpoint molecules in a proportion of CD8 + TILs and Egr2high cells exhibit better survival and proliferation than Egr2-/-Egr3-/- and Egr2low TILs. Anti-PD-1 treatment increases Egr2 expression in CD8 + TILs and reduces tumour growth, while anti-PD-1 efficacy is abrogated in the absence of Egr2 and 3. Thus, Egr2 and 3 are important for maintaining anti-tumour responses of exhausted CD8 + TILs.en_US
dc.description.sponsorshipMedical Research Council UK (MR/N00096X/1); Barts Charity (MGU0463).en_US
dc.format.extent1139 - 1151-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.rightsCopyright © The Author(s) 2022. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectEgr2en_US
dc.subjectEgr3en_US
dc.subjectTumour infiltrating lymphocytesen_US
dc.subjectAnti-PD-1en_US
dc.titleEgr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cellsen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1007/s00262-022-03319-w-
dc.relation.isPartOfCancer Immunology, Immunotherapy-
pubs.issue5-
pubs.publication-statusPublished-
pubs.volume72-
dc.identifier.eissn1432-0851-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderThe Author(s)-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2022. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.5.81 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons